Search results
Results from the WOW.Com Content Network
For premium support please call: 800-290-4726 more ways to reach us
This page was last edited on 3 February 2024, at 22:53 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment ... market will grow at 11% a year through 2033 to $5.7 billion. ... market to grow by 13% a year to ...
The IPO market, particularly technology and fintech, has been rebuilding for a number of quarters, and we expect the market to open up more broadly next year across many core sectors, including ...
Although no clinical development took place, Axovant held its IPO in June 2015 and raised $315 million, [4] the largest biotech IPO ever, [9] based on new phase IIB trials that were more promising. [10] The lock-up period against reselling stock was reduced to an unusually short 90 days for hedge funds that showed interest in the IPO. [11]
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Later that year in December 2022, Roivant and Pfizer announced [24] their third partnership to create a new Vant [25] focused on developing TL1A drug candidates for inflammatory and fibrotic diseases. As of February 2023, Roivant's reported market cap was over $6 billion. [26]
But 2022 was the worst year for IPOs since at least 2010, so last year’s strong rebound performance comes off a much-reduced base, with a large part of the increased volume in the back half of ...